Xeris Pharmaceuticals Inc (XERS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Xeris Pharmaceuticals Inc stock (XERS) is currently trading at $5.30. Xeris Pharmaceuticals Inc PS ratio (Price-to-Sales) is 3.21. Analyst consensus price target for XERS is $11.14. WallStSmart rates XERS as Sell.
- XERS PE ratio analysis and historical PE chart
- XERS PS ratio (Price-to-Sales) history and trend
- XERS intrinsic value — DCF, Graham Number, EPV models
- XERS stock price prediction 2025 2026 2027 2028 2029 2030
- XERS fair value vs current price
- XERS insider transactions and insider buying
- Is XERS undervalued or overvalued?
- Xeris Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- XERS Piotroski F-Score and Altman Z-Score
- XERS analyst price target and Smart Rating
Xeris Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Xeris Pharmaceuticals Inc (XERS) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and price/book. Mixed signals suggest waiting for clearer direction before acting.
Xeris Pharmaceuticals Inc (XERS) Key Strengths (2)
Revenue surging 42.80% year-over-year
59.22% held by institutions, strong professional interest
Supporting Valuation Data
Xeris Pharmaceuticals Inc (XERS) Areas to Watch (6)
Company is destroying shareholder value
Very expensive at 68.7x book value
Very thin margins, barely profitable
Small-cap company with higher risk but more growth potential
Decent operational efficiency, solid but not exceptional
Revenue is fairly priced at 3.21x sales
Supporting Valuation Data
Xeris Pharmaceuticals Inc (XERS) Detailed Analysis Report
Overall Assessment
This company scores 38/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 3.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 42.80%.
The Bear Case
The primary concerns are Return on Equity, Price/Book, Profit Margin. Some valuation metrics including Price/Sales (3.21), Price/Book (68.65) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -617.00%, Operating Margin at 19.60%, Profit Margin at 0.19%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -617.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 42.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
XERS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
XERS's Price-to-Sales ratio of 3.21x sits near its historical average of 3.39x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 16% below its historical high of 3.82x set in Mar 2026, and 0% above its historical low of 3.21x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Xeris Pharmaceuticals Inc (XERS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Xeris Pharmaceuticals Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 292M with 43% growth year-over-year. Profit margins of 19.0% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 43% YoY, reaching 292M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Generating 20M in free cash flow and 20M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Growth sustainability: can Xeris Pharmaceuticals Inc maintain 43%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Xeris Pharmaceuticals Inc.
Bottom Line
Xeris Pharmaceuticals Inc offers an attractive blend of growth (43% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(43 last 3 months)
| Insider | Type | Shares |
|---|---|---|
NGUYEN, ANH TU See Remarks | Sell | -29,300 |
| Insider | Type | Shares |
|---|---|---|
HECHT, BETH See Remarks | Sell | -16,667 |
| Insider | Type | Shares |
|---|---|---|
MCCULLOCH, KEVIN See Remarks | Sell | -15,000 |
| Insider | Type | Shares |
|---|---|---|
HECHT, BETH See Remarks | Sell | -16,667 |
Data sourced from SEC Form 4 filings
Last updated: 8:28:07 AM
About Xeris Pharmaceuticals Inc(XERS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. The company is headquartered in Chicago, Illinois.